JIC
TEVA icon

Joel Isaacson & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Joel Isaacson & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,718
Closed -$207K – 493
2016
Q4 		$207K Sell
5,718
-4,210
-42% -$168K 0.04% 151
2016
Q3 		$457K Sell
9,928
-150
-1% -$7.83K 0.09% 97
2016
Q2 		$506K Hold
10,078
– – 0.11% 84
2016
Q1 		$539K Hold
10,078
– – 0.12% 82
2015
Q4 		$662K Sell
10,078
-84
-0.8% -$5.19K 0.16% 65
2015
Q3 		$574K Buy
10,162
+150
+1% +$9.73K 0.15% 64
2015
Q2 		$592K Hold
10,012
– – 0.15% 72
2015
Q1 		$624K Buy
10,012
+684
+7% +$39.8K 0.16% 69
2014
Q4 		$536K Buy
9,328
+211
+2% +$11.8K 0.14% 70
2014
Q3 		$490K Buy
9,117
+84
+0.9% +$4.45K 0.15% 63
2014
Q2 		$474K Buy
9,033
+35
+0.4% +$1.79K 0.15% 68
2014
Q1 		$475K Hold
8,998
– – 0.16% 64
2013
Q4 		$361K Hold
8,998
– – 0.13% 69
2013
Q3 		$340K Sell
8,998
-600
-6% -$23.4K 0.14% 67
2013
Q2 		$376K Buy
+9,598
New +$374K 0.18% 58

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Joel Isaacson & Co's TEVA Position: Q1 2017 in Review

Joel Isaacson & Co sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 5,718 shares — an estimated $207K sold.

Joel Isaacson & Co first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $662K in Q4 2015. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Joel Isaacson & Co reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Joel Isaacson & Co sold 5,718 Teva Pharmaceuticals shares in Q1 2017, an estimated $207K.
  • Joel Isaacson & Co first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Joel Isaacson & Co's Teva Pharmaceuticals position peaked at $662K in Q4 2015.
  • 686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.